InterHealth’s OptiBerry Shown to Inhibit Angiogenesis

Recent studies published in peer reviewed journals have shown that OptiBerry™, a patent-pending, standardized multiple berry extract developed by InterHealth Nutraceuticals, possesses potent anti-angiogenic properties, which inhibit the growth of unwanted blood vessels involved in the formation of tumors and varicose veins. Researchers at The Ohio State University Medical Center, Columbus, OH, University of Kupio, Kupio, Finland and Creighton University Medical Center, Omaha, NE, have shown that OptiBerry significantly inhibits angiogenesis both in vitro and in vivo, thus offering potential benefit in the treatment of related disorders such as cancer and inflammation. The studies were published in Free Radical Research and the Federation of European Biochemical Societies (FEBS) Letters. OptiBerry contains numerous berry extracts, including wild blueberry, bilberry, cranberry, elderberry, raspberry and strawberry.